Maternal & Child Health Research Institute (MCHRI)
Showing 11-20 of 68 Results
-
Cynthia Kapphahn
Clinical Professor, Pediatrics - Adolescent Medicine
Current Research and Scholarly InterestsAccess to health care services for adolescents.
Confidentiality.
Mental Health Financing.
Eating disorders. -
Ioannis Karakikes
Associate Professor (Research) of Cardiothoracic Surgery
Current Research and Scholarly InterestsThe Karakikes Lab aims to uncover fundamental new insights into the molecular mechanisms and functional consequences of pathogenic mutations associated with familial cardiovascular diseases.
-
Siva Kasinathan
Instructor, Pediatrics - Rheumatology
BioSiva Kasinathan, MD, PhD is a physician-scientist and Instructor of Pediatric Rheumatology at the Stanford University School of Medicine and Lucile Packard Children's Hospital. In addition to caring for children and young adults with rheumatic diseases in his clinical practice, Siva conducts research to advance the understanding of mechanisms of autoimmunity and autoinflammation.
Siva holds an MD and PhD in Molecular and Cell Biology from the University of Washington, where he developed several high-throughput methods for epigenome profiling and contributed new insights in chromatin biology and gene regulation. During his clinical training in pediatrics and rheumatology at Stanford, Siva pioneered approaches for single-molecule analysis of genetic variation, DNA methylation, and chromatin structure, and established a longitudinal rheumatic disease cohort and biorepository.
Siva’s current research bridges genomics and immunology with a focus on developing and applying sensitive technologies to unravel the genetic and molecular underpinnings of lupus, arthritis, and other immune-mediated diseases. As a physician-scientist, Siva is committed to translating fundamental discoveries into precision therapies and biomarkers to improve outcomes for patients with rheumatic diseases. -
Maya M. Kasowski
Assistant Professor of Pathology, of Medicine (Pulmonary, Allergy and Critical Care Medicine) and, by courtesy, of Genetics
BioI am a clinical pathologist and assistant professor in the Departments of Medicine, Pathology, and Genetics (by courtesy) at Stanford. I completed my MD-PhD training at Yale University and my residency training and a post-doctoral fellowship in the Department of Genetics at Stanford University. My experiences as a clinical pathologist and genome scientist have made me passionate about applying cutting-edge technologies to primary patient specimens in order to characterize disease pathologies at the molecular level. The core focus of my lab is to study the mechanisms by which genetic variants influence the risk of disease through effects on intermediate molecular phenotypes.
-
Makoto Kawai
Clinical Professor, Psychiatry and Behavioral Sciences - Sleep Medicine
BioI am a physician scientist in the field of sleep medicine in aging and brain function. Using combined polysomnogram and novel neuroimaging technology, I aim to identify potential sleep biomarkers to investigate the mechanism of progression from normal aging to Mild Cognitive Impairment (MCI) or dementia. I also investigate the impact of sleep on cognitive/affective function or behavior abnormality in various neurodevelopmental and neurodegenerative disorders.
-
Mark A. Kay, M.D., Ph.D.
Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics
Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.
-
Debra Lee Kaysen
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Current Research and Scholarly InterestsMuch of my current research focus is on the development of testing of accessible, scaleable, and effective treatments for trauma-related disorders and related comorbidities (e.g. substance use disorders, HIV, mood disorders). This work has focused on addressing trauma-related disorders especially in underserved populations and settings. This includes research in rural communities, with Native American communities, and with sexual minorities. My research has had a strong impact on building an evidence base on adaptations of psychotherapies for PTSD and substance use disorders for diverse populations both within and outside the United States. Our findings demonstrate that complex cognitive behavioral psychotherapies like Cognitive Processing Therapy can be culturally adapted and delivered in challenging settings (conflict settings, high poverty environments) with significant and lasting change in PTSD, depression, and functioning. This has led to work adapting CPT for diverse populations within the United States (rural Native Americans, urban Latinos) and outside of it (Iraq, DRC). Other research has focused on treatment for PTSD/SUD. My research has also found support for the use of brief telehealth interventions to build treatment engagement and to reduce drinking among trauma-exposed populations. In addition, my work has been critical in testing the feasibility of novel trauma-focused interventions for use by those with PTSD and SUD, thus paving the road for more rigorous research studies.
Current PI'ed research studies include: 1) developing and evaluating a brief motivational interviewing intervention designed to increase treatment-seeking among military personnel with untreated PTSD; a two-arm randomized comparative effectiveness trial to evaluate prevention of HIV/STI sexual risk behavior by addressing PTSD through Narrative Exposure Therapy or substance use through Motivational Interviewing among Native American men and women with PTSD; and 3) a comparison of outcomes among patients randomized to initially receive pharmacotherapy or Written Exposure Therapy delivered in primary care as well as comparing outcomes among patients randomized to treatment sequences (i.e., switching and augmenting) for patients who do not respond to the initial treatment.
